Read more

November 16, 2021
1 min read
Save

Eyes that received Hydrus microstent less likely to require medications after 5 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS — After 5 years of follow-up, eyes that received the Hydrus microstent for mild to moderate glaucoma required fewer medications and surgeries compared with eyes that underwent cataract surgery alone, according to a study.

“This is a continuous follow-up, which I think is important, and we had over 80% of patients that made that follow-up visit,” Ike K. Ahmed, MD, said during a presentation at the American Academy of Ophthalmology meeting.

After phacoemulsification, 556 eyes were randomly assigned to receive the Hydrus microstent (Ivantis) or no additional treatment.

Ike K. Ahmed, MD
Ike Ahmed

Eyes that received microstent were more likely to be medication-free at 5 years, with 66% of patients not requiring medications vs. 46% of patients who underwent cataract surgery alone (P < .001). Eyes that received a microstent also experienced a greater reduction in medication-free IOP vs. baseline, 8.3 ± 3.8 mm Hg compared with 6.5 ± 4 mm Hg (P < .001).

Additionally, eyes that received a microstent were less likely to require incisional glaucoma surgery, with 2.5% of microstent eyes requiring surgery compared with 6.4% of eyes that underwent cataract surgery alone (P = .022).

“Safety is something that is important for all MIGS procedures, and perhaps even more so after the CyPass (Alcon) withdrawal,” Ahmed said. “I think we can say, over 5 years, this is a very safe device, and we have zero concerns over endothelial cell loss.”

“Not to be dramatic, but I think this is pretty important news in the glaucoma space and in medicine,” Ahmed said during a question and answer session after the presentation.